Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Graft vs Host Disease | 234 | 2024 | 3043 | 16.670 |
Why?
|
Hematopoietic Stem Cell Transplantation | 238 | 2024 | 5711 | 11.550 |
Why?
|
Transplantation Conditioning | 98 | 2024 | 1600 | 6.510 |
Why?
|
Myelodysplastic Syndromes | 52 | 2024 | 1399 | 5.760 |
Why?
|
Cord Blood Stem Cell Transplantation | 33 | 2021 | 305 | 5.350 |
Why?
|
Transplantation, Homologous | 126 | 2024 | 4834 | 3.970 |
Why?
|
Hematologic Neoplasms | 61 | 2024 | 1906 | 3.750 |
Why?
|
Sirolimus | 25 | 2020 | 1542 | 3.040 |
Why?
|
Tacrolimus | 23 | 2023 | 750 | 2.130 |
Why?
|
Leukemia, Myeloid, Acute | 34 | 2024 | 3620 | 2.000 |
Why?
|
Immunosuppressive Agents | 37 | 2024 | 4209 | 1.930 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 15 | 2016 | 263 | 1.700 |
Why?
|
Leukemia | 17 | 2021 | 1526 | 1.570 |
Why?
|
Chronic Disease | 100 | 2024 | 9380 | 1.530 |
Why?
|
Fetal Blood | 17 | 2022 | 1361 | 1.510 |
Why?
|
Mouth Diseases | 8 | 2024 | 239 | 1.250 |
Why?
|
Hepatic Veno-Occlusive Disease | 9 | 2022 | 220 | 1.190 |
Why?
|
Interleukin-2 | 14 | 2022 | 1894 | 1.170 |
Why?
|
Bone Marrow Transplantation | 16 | 2023 | 2709 | 1.150 |
Why?
|
Methotrexate | 18 | 2022 | 1722 | 1.050 |
Why?
|
Histocompatibility Testing | 20 | 2021 | 716 | 1.000 |
Why?
|
Stem Cell Transplantation | 14 | 2020 | 1601 | 0.920 |
Why?
|
Acetamides | 3 | 2023 | 260 | 0.920 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 8 | 2014 | 695 | 0.910 |
Why?
|
Middle Aged | 233 | 2024 | 223463 | 0.890 |
Why?
|
Disease-Free Survival | 53 | 2023 | 6856 | 0.890 |
Why?
|
National Institutes of Health (U.S.) | 14 | 2022 | 794 | 0.870 |
Why?
|
Humans | 384 | 2024 | 768298 | 0.870 |
Why?
|
Adult | 232 | 2024 | 223622 | 0.830 |
Why?
|
Myeloablative Agonists | 14 | 2018 | 210 | 0.800 |
Why?
|
HLA Antigens | 10 | 2019 | 1337 | 0.790 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 3 | 2023 | 1428 | 0.790 |
Why?
|
Aged | 176 | 2024 | 171544 | 0.760 |
Why?
|
T-Lymphocytes, Regulatory | 20 | 2022 | 3111 | 0.710 |
Why?
|
Male | 231 | 2024 | 364870 | 0.700 |
Why?
|
Survival Analysis | 51 | 2019 | 10117 | 0.700 |
Why?
|
Vidarabine | 12 | 2021 | 337 | 0.690 |
Why?
|
Histocompatibility | 6 | 2016 | 322 | 0.680 |
Why?
|
Recurrence | 46 | 2024 | 8501 | 0.670 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 2014 | 646 | 0.660 |
Why?
|
Female | 232 | 2024 | 397050 | 0.640 |
Why?
|
Adrenal Cortex Hormones | 7 | 2020 | 1890 | 0.640 |
Why?
|
Bronchiolitis Obliterans | 7 | 2022 | 220 | 0.620 |
Why?
|
Busulfan | 11 | 2021 | 259 | 0.620 |
Why?
|
Intention to Treat Analysis | 3 | 2021 | 417 | 0.620 |
Why?
|
Acute Disease | 32 | 2020 | 7242 | 0.620 |
Why?
|
B-Lymphocytes | 14 | 2022 | 4785 | 0.610 |
Why?
|
Survival Rate | 43 | 2021 | 12870 | 0.600 |
Why?
|
Consensus | 11 | 2024 | 3212 | 0.580 |
Why?
|
Transplantation, Autologous | 13 | 2024 | 2127 | 0.570 |
Why?
|
Mouth Mucosa | 5 | 2024 | 437 | 0.570 |
Why?
|
Steroids | 9 | 2023 | 936 | 0.560 |
Why?
|
Hematology | 1 | 2020 | 244 | 0.560 |
Why?
|
B-Cell Activating Factor | 8 | 2018 | 116 | 0.560 |
Why?
|
Graft vs Leukemia Effect | 6 | 2020 | 121 | 0.520 |
Why?
|
Anemia, Aplastic | 2 | 2015 | 231 | 0.510 |
Why?
|
Young Adult | 89 | 2024 | 60048 | 0.510 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 8 | 2018 | 1558 | 0.510 |
Why?
|
Blood Donors | 5 | 2019 | 344 | 0.500 |
Why?
|
Radiopharmaceuticals | 4 | 2020 | 2734 | 0.500 |
Why?
|
Consumer Health Information | 1 | 2017 | 215 | 0.490 |
Why?
|
Treatment Outcome | 67 | 2024 | 65365 | 0.480 |
Why?
|
Graft Survival | 16 | 2021 | 3900 | 0.470 |
Why?
|
Lymphoma | 7 | 2016 | 1907 | 0.470 |
Why?
|
Piperidines | 4 | 2021 | 1660 | 0.470 |
Why?
|
Access to Information | 1 | 2017 | 317 | 0.470 |
Why?
|
Whole-Body Irradiation | 5 | 2019 | 435 | 0.460 |
Why?
|
Prognosis | 41 | 2023 | 30020 | 0.460 |
Why?
|
Oral Medicine | 2 | 2016 | 36 | 0.460 |
Why?
|
Patient Selection | 2 | 2020 | 4265 | 0.450 |
Why?
|
Azacitidine | 3 | 2024 | 335 | 0.450 |
Why?
|
Protein Kinase Inhibitors | 5 | 2021 | 5707 | 0.450 |
Why?
|
16,16-Dimethylprostaglandin E2 | 1 | 2013 | 22 | 0.450 |
Why?
|
BK Virus | 3 | 2020 | 120 | 0.430 |
Why?
|
Stomatitis | 4 | 2016 | 271 | 0.420 |
Why?
|
Adolescent | 86 | 2024 | 89182 | 0.420 |
Why?
|
Sezary Syndrome | 3 | 2024 | 80 | 0.420 |
Why?
|
Clinical Trials as Topic | 14 | 2022 | 8051 | 0.420 |
Why?
|
Mycosis Fungoides | 4 | 2024 | 169 | 0.410 |
Why?
|
Peer Review, Research | 1 | 2016 | 344 | 0.410 |
Why?
|
Elafin | 1 | 2012 | 30 | 0.410 |
Why?
|
Receptors, KIR | 1 | 2013 | 114 | 0.410 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2018 | 683 | 0.410 |
Why?
|
Melphalan | 6 | 2020 | 421 | 0.400 |
Why?
|
Quality of Life | 24 | 2024 | 13499 | 0.400 |
Why?
|
Retrospective Studies | 77 | 2024 | 81768 | 0.400 |
Why?
|
Comprehension | 1 | 2017 | 641 | 0.400 |
Why?
|
Nuclear Medicine | 1 | 2015 | 262 | 0.390 |
Why?
|
Antibodies, Monoclonal | 12 | 2022 | 9261 | 0.390 |
Why?
|
Prospective Studies | 47 | 2024 | 54921 | 0.390 |
Why?
|
Germinal Center | 3 | 2022 | 380 | 0.380 |
Why?
|
Skin Diseases | 7 | 2020 | 1084 | 0.380 |
Why?
|
Antibodies | 4 | 2017 | 2425 | 0.370 |
Why?
|
Recovery of Function | 2 | 2019 | 2990 | 0.370 |
Why?
|
Lymphoma, B-Cell | 3 | 2017 | 945 | 0.370 |
Why?
|
CD8-Positive T-Lymphocytes | 13 | 2022 | 4647 | 0.370 |
Why?
|
Tissue Donors | 19 | 2023 | 2389 | 0.370 |
Why?
|
Severity of Illness Index | 21 | 2024 | 15939 | 0.370 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2023 | 4069 | 0.360 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 6 | 2021 | 1643 | 0.360 |
Why?
|
Siblings | 9 | 2019 | 829 | 0.360 |
Why?
|
Cyclophosphamide | 7 | 2023 | 2226 | 0.350 |
Why?
|
Photopheresis | 3 | 2019 | 36 | 0.340 |
Why?
|
Angiogenesis Inducing Agents | 3 | 2016 | 254 | 0.340 |
Why?
|
Primary Myelofibrosis | 2 | 2023 | 209 | 0.340 |
Why?
|
Cytomegalovirus Infections | 4 | 2023 | 839 | 0.330 |
Why?
|
Immunoconjugates | 1 | 2017 | 969 | 0.330 |
Why?
|
Leukemia, Myelomonocytic, Chronic | 2 | 2023 | 93 | 0.320 |
Why?
|
Leukemia, Myeloid | 6 | 2021 | 693 | 0.320 |
Why?
|
Lectins, C-Type | 1 | 2012 | 591 | 0.320 |
Why?
|
Decision Support Techniques | 4 | 2024 | 2005 | 0.320 |
Why?
|
Skin Neoplasms | 5 | 2024 | 5857 | 0.310 |
Why?
|
Killer Cells, Natural | 8 | 2022 | 2207 | 0.310 |
Why?
|
Language | 1 | 2017 | 1558 | 0.300 |
Why?
|
Drug Resistance | 4 | 2019 | 1595 | 0.300 |
Why?
|
Transplantation Chimera | 6 | 2015 | 594 | 0.300 |
Why?
|
fms-Like Tyrosine Kinase 3 | 3 | 2016 | 494 | 0.290 |
Why?
|
Telomerase | 3 | 2021 | 752 | 0.290 |
Why?
|
Survivors | 9 | 2024 | 2382 | 0.280 |
Why?
|
rho-Associated Kinases | 2 | 2021 | 286 | 0.280 |
Why?
|
Remission Induction | 10 | 2021 | 2407 | 0.270 |
Why?
|
Virus Activation | 3 | 2019 | 322 | 0.270 |
Why?
|
Antineoplastic Agents | 11 | 2016 | 13696 | 0.260 |
Why?
|
Iron Overload | 4 | 2012 | 246 | 0.260 |
Why?
|
United States | 31 | 2024 | 73144 | 0.260 |
Why?
|
Combined Modality Therapy | 11 | 2019 | 8562 | 0.250 |
Why?
|
Lymphoma, T-Cell, Peripheral | 2 | 2022 | 125 | 0.250 |
Why?
|
Premedication | 2 | 2008 | 246 | 0.250 |
Why?
|
Diagnostic Imaging | 2 | 2020 | 3541 | 0.250 |
Why?
|
Pyrimidines | 6 | 2019 | 3048 | 0.250 |
Why?
|
Drugs, Generic | 1 | 2010 | 454 | 0.250 |
Why?
|
Internet | 1 | 2017 | 3107 | 0.250 |
Why?
|
Antigens, Neoplasm | 2 | 2012 | 1999 | 0.240 |
Why?
|
Drug Hypersensitivity | 2 | 2024 | 923 | 0.240 |
Why?
|
Polyomavirus Infections | 2 | 2019 | 192 | 0.240 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2017 | 2171 | 0.240 |
Why?
|
T-Lymphocytes, Helper-Inducer | 5 | 2019 | 977 | 0.240 |
Why?
|
Follow-Up Studies | 29 | 2023 | 39405 | 0.240 |
Why?
|
Copper Radioisotopes | 3 | 2000 | 100 | 0.240 |
Why?
|
Mouth Neoplasms | 2 | 2022 | 597 | 0.240 |
Why?
|
Hemolytic-Uremic Syndrome | 1 | 2005 | 106 | 0.240 |
Why?
|
Antilymphocyte Serum | 4 | 2016 | 491 | 0.240 |
Why?
|
Receptor, Macrophage Colony-Stimulating Factor | 1 | 2024 | 94 | 0.230 |
Why?
|
Time Factors | 22 | 2024 | 40267 | 0.230 |
Why?
|
Lymphocyte Transfusion | 2 | 2016 | 232 | 0.230 |
Why?
|
Hematopoietic Stem Cells | 5 | 2020 | 3407 | 0.230 |
Why?
|
Tumor Virus Infections | 2 | 2019 | 438 | 0.230 |
Why?
|
Penicillins | 2 | 2024 | 406 | 0.230 |
Why?
|
Antigens, CD34 | 2 | 2024 | 656 | 0.230 |
Why?
|
Cohort Studies | 29 | 2022 | 41791 | 0.230 |
Why?
|
HLA-C Antigens | 3 | 2016 | 146 | 0.220 |
Why?
|
T-Lymphocyte Subsets | 5 | 2019 | 1813 | 0.220 |
Why?
|
Incidence | 24 | 2023 | 21544 | 0.220 |
Why?
|
Antigens, Surface | 3 | 2017 | 1616 | 0.220 |
Why?
|
Blood Platelets | 2 | 2013 | 2476 | 0.210 |
Why?
|
Niacinamide | 2 | 2016 | 417 | 0.210 |
Why?
|
Treatment Failure | 4 | 2024 | 2664 | 0.210 |
Why?
|
Hematopoietic Stem Cell Mobilization | 3 | 2016 | 225 | 0.210 |
Why?
|
Graft Rejection | 5 | 2014 | 4505 | 0.210 |
Why?
|
Age Factors | 15 | 2024 | 18472 | 0.210 |
Why?
|
Activated-Leukocyte Cell Adhesion Molecule | 1 | 2022 | 21 | 0.210 |
Why?
|
T-Lymphocytes | 7 | 2020 | 10266 | 0.210 |
Why?
|
Dental Caries | 3 | 2023 | 429 | 0.210 |
Why?
|
Gastrointestinal Agents | 2 | 2019 | 510 | 0.210 |
Why?
|
DNA Methylation | 2 | 2014 | 4419 | 0.210 |
Why?
|
Genome, Mitochondrial | 1 | 2023 | 68 | 0.210 |
Why?
|
Prednisone | 5 | 2021 | 1568 | 0.210 |
Why?
|
Pyrazoles | 3 | 2019 | 2021 | 0.200 |
Why?
|
Living Donors | 5 | 2015 | 650 | 0.200 |
Why?
|
Telomere | 2 | 2020 | 943 | 0.200 |
Why?
|
Gastrointestinal Tract | 3 | 2020 | 839 | 0.200 |
Why?
|
Phenylurea Compounds | 2 | 2016 | 529 | 0.200 |
Why?
|
Immunoblastic Lymphadenopathy | 1 | 2022 | 40 | 0.200 |
Why?
|
Enzyme Inhibitors | 3 | 2022 | 3722 | 0.200 |
Why?
|
Adenine | 4 | 2021 | 993 | 0.200 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2014 | 4357 | 0.200 |
Why?
|
Immunologic Memory | 5 | 2017 | 1374 | 0.190 |
Why?
|
Mutation | 11 | 2023 | 30230 | 0.190 |
Why?
|
Gallium Radioisotopes | 2 | 2020 | 195 | 0.190 |
Why?
|
Isoantibodies | 3 | 2019 | 682 | 0.190 |
Why?
|
Lymphocyte Activation | 11 | 2022 | 5496 | 0.190 |
Why?
|
Markov Chains | 3 | 2013 | 977 | 0.190 |
Why?
|
Administration, Topical | 2 | 2020 | 703 | 0.190 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 2 | 2018 | 190 | 0.180 |
Why?
|
Opportunistic Infections | 1 | 2023 | 375 | 0.180 |
Why?
|
CD4-Positive T-Lymphocytes | 9 | 2020 | 4411 | 0.180 |
Why?
|
Child | 32 | 2024 | 80894 | 0.180 |
Why?
|
Xerostomia | 1 | 2021 | 94 | 0.180 |
Why?
|
Boronic Acids | 3 | 2014 | 915 | 0.180 |
Why?
|
Follistatin | 2 | 2019 | 138 | 0.180 |
Why?
|
Muscle Strength | 1 | 2024 | 641 | 0.170 |
Why?
|
Protein Kinases | 2 | 2022 | 1609 | 0.170 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 1 | 2022 | 168 | 0.170 |
Why?
|
Hematologic Diseases | 4 | 2018 | 499 | 0.170 |
Why?
|
Child, Preschool | 23 | 2019 | 42654 | 0.170 |
Why?
|
Leukemia, Experimental | 1 | 2020 | 225 | 0.170 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 1 | 2023 | 271 | 0.160 |
Why?
|
Receptors, CXCR5 | 2 | 2016 | 88 | 0.160 |
Why?
|
Social Class | 2 | 2018 | 2008 | 0.160 |
Why?
|
Peer Group | 1 | 2024 | 698 | 0.160 |
Why?
|
Pyrazines | 3 | 2014 | 1206 | 0.160 |
Why?
|
Isotope Labeling | 1 | 2000 | 395 | 0.160 |
Why?
|
Societies | 1 | 1999 | 107 | 0.150 |
Why?
|
Kaplan-Meier Estimate | 9 | 2021 | 6541 | 0.150 |
Why?
|
Choroid Neoplasms | 1 | 1999 | 177 | 0.150 |
Why?
|
Maximum Tolerated Dose | 2 | 2019 | 890 | 0.150 |
Why?
|
Pulmonary Blastoma | 1 | 1998 | 43 | 0.150 |
Why?
|
Patient Education as Topic | 3 | 2017 | 2337 | 0.150 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 4 | 2022 | 892 | 0.150 |
Why?
|
Cytokines | 5 | 2019 | 7443 | 0.150 |
Why?
|
Endothelium, Vascular | 1 | 2010 | 4427 | 0.150 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2021 | 654 | 0.150 |
Why?
|
Fibrosis | 2 | 2024 | 2076 | 0.140 |
Why?
|
Receptors, Antigen, T-Cell | 5 | 2019 | 2568 | 0.140 |
Why?
|
Immunologic Factors | 3 | 2014 | 1598 | 0.140 |
Why?
|
North America | 2 | 2018 | 1290 | 0.140 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 1 | 2020 | 434 | 0.140 |
Why?
|
Skin | 4 | 2020 | 4499 | 0.140 |
Why?
|
Salvage Therapy | 3 | 2018 | 1277 | 0.140 |
Why?
|
Prednisolone | 1 | 2018 | 327 | 0.140 |
Why?
|
Medicaid | 1 | 2011 | 2842 | 0.140 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2023 | 617 | 0.140 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 2 | 2016 | 306 | 0.140 |
Why?
|
alpha 1-Antitrypsin | 1 | 2018 | 169 | 0.140 |
Why?
|
Myeloproliferative Disorders | 3 | 2016 | 614 | 0.140 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2023 | 9433 | 0.140 |
Why?
|
Sulfonamides | 2 | 2024 | 1980 | 0.140 |
Why?
|
Thrombotic Microangiopathies | 1 | 2018 | 124 | 0.140 |
Why?
|
Search Engine | 1 | 2017 | 142 | 0.130 |
Why?
|
Graft vs Tumor Effect | 1 | 2016 | 68 | 0.130 |
Why?
|
Cryopreservation | 3 | 2021 | 733 | 0.130 |
Why?
|
Animals | 27 | 2022 | 169322 | 0.130 |
Why?
|
Neoplasms, Second Primary | 2 | 2017 | 1060 | 0.130 |
Why?
|
Risk Factors | 25 | 2018 | 74954 | 0.130 |
Why?
|
Immunotherapy, Adoptive | 3 | 2021 | 1508 | 0.130 |
Why?
|
Donor Selection | 1 | 2018 | 240 | 0.130 |
Why?
|
Cancer Vaccines | 3 | 2014 | 1042 | 0.130 |
Why?
|
Early Diagnosis | 1 | 2021 | 1195 | 0.130 |
Why?
|
Medicare | 3 | 2024 | 6881 | 0.130 |
Why?
|
Guidelines as Topic | 2 | 2020 | 1397 | 0.130 |
Why?
|
Arabinonucleosides | 1 | 2015 | 34 | 0.130 |
Why?
|
Neoplasm, Residual | 2 | 2021 | 1019 | 0.130 |
Why?
|
Tandem Repeat Sequences | 1 | 2016 | 183 | 0.120 |
Why?
|
Adenine Nucleotides | 1 | 2015 | 110 | 0.120 |
Why?
|
Organometallic Compounds | 1 | 1999 | 648 | 0.120 |
Why?
|
Outpatients | 1 | 2023 | 1603 | 0.120 |
Why?
|
Blood Specimen Collection | 1 | 2016 | 238 | 0.120 |
Why?
|
Inpatients | 2 | 2024 | 2569 | 0.120 |
Why?
|
Glutamate Carboxypeptidase II | 1 | 2015 | 90 | 0.120 |
Why?
|
Stem Cell Factor | 1 | 2015 | 194 | 0.120 |
Why?
|
Receptors, CXCR3 | 1 | 2016 | 241 | 0.120 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 9 | 2018 | 11854 | 0.120 |
Why?
|
Interleukin-7 | 1 | 2015 | 145 | 0.120 |
Why?
|
Chemokine CXCL10 | 1 | 2016 | 311 | 0.120 |
Why?
|
Mediastinal Neoplasms | 1 | 2017 | 403 | 0.120 |
Why?
|
Flow Cytometry | 6 | 2018 | 5898 | 0.120 |
Why?
|
Research Support as Topic | 1 | 1999 | 696 | 0.120 |
Why?
|
Oral Health | 1 | 2020 | 493 | 0.120 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 906 | 0.120 |
Why?
|
Registries | 5 | 2018 | 8378 | 0.120 |
Why?
|
Antigens, CD19 | 1 | 2017 | 437 | 0.120 |
Why?
|
Antifungal Agents | 2 | 2012 | 757 | 0.120 |
Why?
|
Hypersensitivity | 1 | 2023 | 1172 | 0.120 |
Why?
|
Monte Carlo Method | 1 | 2020 | 1260 | 0.120 |
Why?
|
Epidermal Growth Factor | 1 | 2017 | 698 | 0.120 |
Why?
|
Thrombomodulin | 2 | 2016 | 107 | 0.110 |
Why?
|
Endpoint Determination | 1 | 2017 | 594 | 0.110 |
Why?
|
Holmium | 1 | 2013 | 29 | 0.110 |
Why?
|
Lymphocyte Depletion | 4 | 2016 | 605 | 0.110 |
Why?
|
Bone Marrow | 5 | 2023 | 2929 | 0.110 |
Why?
|
Lymphocyte Count | 4 | 2019 | 793 | 0.110 |
Why?
|
Thermodynamics | 1 | 2015 | 590 | 0.110 |
Why?
|
Drug Therapy, Combination | 6 | 2016 | 6319 | 0.110 |
Why?
|
Adoptive Transfer | 1 | 2016 | 824 | 0.110 |
Why?
|
Radioimmunotherapy | 1 | 2013 | 93 | 0.110 |
Why?
|
Antigen-Presenting Cells | 2 | 2020 | 962 | 0.110 |
Why?
|
Managed Care Programs | 1 | 1999 | 942 | 0.110 |
Why?
|
Varicose Veins | 1 | 1995 | 157 | 0.110 |
Why?
|
Ferritins | 4 | 2012 | 601 | 0.110 |
Why?
|
Glucagon | 1 | 1995 | 534 | 0.110 |
Why?
|
Fascia | 1 | 2014 | 143 | 0.110 |
Why?
|
B-Lymphocyte Subsets | 2 | 2018 | 241 | 0.110 |
Why?
|
Consensus Development Conferences, NIH as Topic | 4 | 2014 | 29 | 0.110 |
Why?
|
Data Collection | 4 | 2018 | 3324 | 0.110 |
Why?
|
Practice Guidelines as Topic | 7 | 2024 | 7453 | 0.110 |
Why?
|
Small Molecule Libraries | 1 | 2018 | 743 | 0.100 |
Why?
|
Neoplasms | 5 | 2023 | 22389 | 0.100 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 1088 | 0.100 |
Why?
|
Prostatic Neoplasms | 1 | 2015 | 11220 | 0.100 |
Why?
|
Disease Management | 2 | 2020 | 2536 | 0.100 |
Why?
|
Cyclosporine | 1 | 2015 | 779 | 0.100 |
Why?
|
Viremia | 2 | 2019 | 725 | 0.100 |
Why?
|
Joints | 1 | 2014 | 324 | 0.100 |
Why?
|
Qualitative Research | 1 | 2023 | 3131 | 0.100 |
Why?
|
Limbic Encephalitis | 1 | 2012 | 36 | 0.100 |
Why?
|
Leukocytes, Mononuclear | 2 | 2016 | 1855 | 0.100 |
Why?
|
Chelation Therapy | 1 | 2012 | 77 | 0.100 |
Why?
|
Employment | 1 | 2018 | 1116 | 0.100 |
Why?
|
Roseolovirus Infections | 1 | 2012 | 50 | 0.100 |
Why?
|
Mutagenesis, Insertional | 1 | 2014 | 662 | 0.100 |
Why?
|
Topography, Medical | 1 | 2011 | 37 | 0.100 |
Why?
|
STAT3 Transcription Factor | 1 | 2016 | 875 | 0.100 |
Why?
|
Gene Deletion | 1 | 2019 | 2673 | 0.100 |
Why?
|
Herpesvirus 6, Human | 1 | 2012 | 98 | 0.100 |
Why?
|
Homeostasis | 3 | 2013 | 3349 | 0.090 |
Why?
|
Pyridones | 1 | 2017 | 818 | 0.090 |
Why?
|
Procarbazine | 1 | 2011 | 172 | 0.090 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2014 | 2066 | 0.090 |
Why?
|
Granulocyte Colony-Stimulating Factor | 2 | 2016 | 631 | 0.090 |
Why?
|
Saccharomyces cerevisiae | 1 | 2022 | 2678 | 0.090 |
Why?
|
Radionuclide Imaging | 1 | 2015 | 1998 | 0.090 |
Why?
|
Iron Chelating Agents | 1 | 2012 | 141 | 0.090 |
Why?
|
Drug Administration Routes | 1 | 2011 | 151 | 0.090 |
Why?
|
Mycophenolic Acid | 2 | 2010 | 350 | 0.090 |
Why?
|
Phantoms, Imaging | 1 | 2020 | 2528 | 0.090 |
Why?
|
DNA, Neoplasm | 1 | 2016 | 1748 | 0.090 |
Why?
|
Caregivers | 1 | 2023 | 2303 | 0.090 |
Why?
|
Delirium | 1 | 2023 | 1695 | 0.090 |
Why?
|
Aftercare | 1 | 2017 | 920 | 0.090 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2009 | 1376 | 0.090 |
Why?
|
Kinetics | 2 | 2015 | 6334 | 0.090 |
Why?
|
STAT5 Transcription Factor | 3 | 2017 | 268 | 0.090 |
Why?
|
Therapeutic Equivalency | 1 | 2010 | 134 | 0.090 |
Why?
|
Cytomegalovirus | 2 | 2018 | 754 | 0.090 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2014 | 618 | 0.090 |
Why?
|
Bone Marrow Diseases | 1 | 2012 | 234 | 0.090 |
Why?
|
Acute Kidney Injury | 1 | 2023 | 1943 | 0.090 |
Why?
|
Sickness Impact Profile | 1 | 2011 | 299 | 0.090 |
Why?
|
Age of Onset | 1 | 2017 | 3345 | 0.090 |
Why?
|
Melanoma, Experimental | 1 | 2013 | 559 | 0.090 |
Why?
|
Multiple Myeloma | 2 | 2024 | 5192 | 0.090 |
Why?
|
Clostridium Infections | 1 | 2017 | 560 | 0.090 |
Why?
|
International Cooperation | 2 | 2014 | 1438 | 0.090 |
Why?
|
Hand Strength | 1 | 2013 | 466 | 0.090 |
Why?
|
Immunophenotyping | 4 | 2018 | 1866 | 0.080 |
Why?
|
Gastrointestinal Diseases | 1 | 2018 | 1207 | 0.080 |
Why?
|
Vinblastine | 1 | 2011 | 488 | 0.080 |
Why?
|
Haplotypes | 1 | 2016 | 2724 | 0.080 |
Why?
|
Tissue Distribution | 3 | 2013 | 2298 | 0.080 |
Why?
|
Proteins | 2 | 2022 | 6006 | 0.080 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2017 | 2433 | 0.080 |
Why?
|
Pilot Projects | 5 | 2024 | 8730 | 0.080 |
Why?
|
Antibody Specificity | 1 | 2011 | 1065 | 0.080 |
Why?
|
Mucocele | 1 | 2009 | 51 | 0.080 |
Why?
|
Isoantigens | 1 | 2012 | 563 | 0.080 |
Why?
|
Diagnostic Techniques, Ophthalmological | 1 | 2011 | 251 | 0.080 |
Why?
|
Mice, Inbred BALB C | 4 | 2020 | 6228 | 0.080 |
Why?
|
Diarrhea | 2 | 2017 | 1320 | 0.080 |
Why?
|
Longitudinal Studies | 5 | 2018 | 14783 | 0.080 |
Why?
|
Erythema | 1 | 2010 | 261 | 0.080 |
Why?
|
Neoplasm Proteins | 1 | 2021 | 3609 | 0.080 |
Why?
|
Transforming Growth Factor beta | 1 | 2017 | 2003 | 0.080 |
Why?
|
Genetic Variation | 2 | 2021 | 6606 | 0.080 |
Why?
|
Intestine, Small | 1 | 1995 | 1218 | 0.080 |
Why?
|
History, 21st Century | 1 | 2015 | 1575 | 0.080 |
Why?
|
Artificial Intelligence | 1 | 2023 | 2661 | 0.080 |
Why?
|
Oral Ulcer | 1 | 2009 | 96 | 0.080 |
Why?
|
Dexamethasone | 1 | 2016 | 1965 | 0.080 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2009 | 187 | 0.080 |
Why?
|
Medical Oncology | 2 | 2023 | 2348 | 0.080 |
Why?
|
Endoscopy, Gastrointestinal | 1 | 1995 | 887 | 0.080 |
Why?
|
Thrombocytopenia | 1 | 2016 | 1180 | 0.080 |
Why?
|
Proportional Hazards Models | 8 | 2017 | 12557 | 0.080 |
Why?
|
Hypertriglyceridemia | 1 | 2011 | 293 | 0.080 |
Why?
|
Aminoglycosides | 2 | 2012 | 159 | 0.080 |
Why?
|
Mice, Inbred C57BL | 8 | 2020 | 22355 | 0.080 |
Why?
|
Dose-Response Relationship, Drug | 6 | 2024 | 10776 | 0.070 |
Why?
|
Neoplasm Staging | 2 | 2020 | 11254 | 0.070 |
Why?
|
Cross Infection | 1 | 2017 | 1422 | 0.070 |
Why?
|
Myocardium | 2 | 2012 | 4788 | 0.070 |
Why?
|
Drug Monitoring | 2 | 2012 | 964 | 0.070 |
Why?
|
Spleen | 2 | 2016 | 2295 | 0.070 |
Why?
|
Risk | 5 | 2011 | 9635 | 0.070 |
Why?
|
Lymphoproliferative Disorders | 1 | 2011 | 529 | 0.070 |
Why?
|
E-Selectin | 1 | 2010 | 578 | 0.070 |
Why?
|
Pulmonary Edema | 1 | 2010 | 409 | 0.070 |
Why?
|
Mice | 13 | 2022 | 82004 | 0.070 |
Why?
|
Antibodies, Viral | 3 | 2019 | 3211 | 0.070 |
Why?
|
Range of Motion, Articular | 1 | 2014 | 1599 | 0.070 |
Why?
|
Drug Evaluation | 2 | 2006 | 642 | 0.070 |
Why?
|
Multivariate Analysis | 7 | 2017 | 12092 | 0.070 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2017 | 2950 | 0.070 |
Why?
|
Insurance Coverage | 1 | 2018 | 1946 | 0.070 |
Why?
|
Dry Eye Syndromes | 1 | 2011 | 383 | 0.070 |
Why?
|
Hypolipidemic Agents | 1 | 2011 | 609 | 0.070 |
Why?
|
Cost-Benefit Analysis | 2 | 2024 | 5538 | 0.070 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2010 | 450 | 0.070 |
Why?
|
Cytogenetics | 1 | 2007 | 198 | 0.070 |
Why?
|
Drug Administration Schedule | 2 | 2012 | 4859 | 0.070 |
Why?
|
Lymphoma, Follicular | 1 | 2011 | 460 | 0.070 |
Why?
|
Ancillary Services, Hospital | 1 | 2006 | 23 | 0.070 |
Why?
|
RNA | 1 | 2016 | 2726 | 0.070 |
Why?
|
Drug Stability | 2 | 2013 | 291 | 0.070 |
Why?
|
Immunity, Humoral | 1 | 2010 | 611 | 0.070 |
Why?
|
Cells, Cultured | 4 | 2016 | 19019 | 0.070 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2010 | 1133 | 0.070 |
Why?
|
von Willebrand Factor | 1 | 2010 | 680 | 0.060 |
Why?
|
Leukocytes | 1 | 2014 | 2030 | 0.060 |
Why?
|
Antigens, CD | 4 | 2022 | 4031 | 0.060 |
Why?
|
Heart | 1 | 1999 | 4449 | 0.060 |
Why?
|
Transplantation Immunology | 3 | 2016 | 538 | 0.060 |
Why?
|
Case-Control Studies | 7 | 2016 | 22292 | 0.060 |
Why?
|
Infant | 7 | 2017 | 36512 | 0.060 |
Why?
|
Walking | 1 | 2013 | 1201 | 0.060 |
Why?
|
Parathyroid Hormone | 1 | 2012 | 1804 | 0.060 |
Why?
|
Aged, 80 and over | 10 | 2024 | 59683 | 0.060 |
Why?
|
Mice, Knockout | 5 | 2020 | 14481 | 0.060 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 1 | 2007 | 210 | 0.060 |
Why?
|
Iron | 2 | 2012 | 1815 | 0.060 |
Why?
|
Medical Staff, Hospital | 1 | 2009 | 603 | 0.060 |
Why?
|
H-Y Antigen | 1 | 2004 | 42 | 0.060 |
Why?
|
Phototherapy | 1 | 2008 | 367 | 0.060 |
Why?
|
Mice, Mutant Strains | 2 | 2019 | 1755 | 0.060 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2015 | 2889 | 0.060 |
Why?
|
Infusions, Intravenous | 2 | 2024 | 2226 | 0.060 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2012 | 1795 | 0.060 |
Why?
|
Thymus Gland | 1 | 2010 | 1266 | 0.060 |
Why?
|
Peptides | 2 | 2015 | 4352 | 0.060 |
Why?
|
Patients | 2 | 2023 | 909 | 0.060 |
Why?
|
Hypercholesterolemia | 1 | 2011 | 1142 | 0.060 |
Why?
|
Fusion Proteins, bcr-abl | 1 | 2006 | 424 | 0.060 |
Why?
|
Liver Diseases | 1 | 2013 | 1301 | 0.060 |
Why?
|
Feasibility Studies | 3 | 2023 | 5311 | 0.060 |
Why?
|
Cardiology | 1 | 2015 | 1701 | 0.060 |
Why?
|
Length of Stay | 3 | 2008 | 6516 | 0.060 |
Why?
|
Syndrome | 3 | 2018 | 3275 | 0.060 |
Why?
|
Lung Neoplasms | 2 | 1999 | 13576 | 0.060 |
Why?
|
Sclerosis | 1 | 2024 | 213 | 0.060 |
Why?
|
Dental Prophylaxis | 1 | 2023 | 27 | 0.060 |
Why?
|
Organ Specificity | 3 | 2014 | 1966 | 0.060 |
Why?
|
Purpura, Thrombotic Thrombocytopenic | 1 | 2005 | 131 | 0.060 |
Why?
|
Venous Thromboembolism | 1 | 2017 | 1881 | 0.060 |
Why?
|
Chemokines | 1 | 2008 | 962 | 0.050 |
Why?
|
Diphtheria Toxin | 1 | 2004 | 253 | 0.050 |
Why?
|
Observer Variation | 1 | 2009 | 2623 | 0.050 |
Why?
|
Positron-Emission Tomography | 1 | 2020 | 6670 | 0.050 |
Why?
|
Dendritic Cells | 1 | 2014 | 2749 | 0.050 |
Why?
|
Statistics as Topic | 1 | 2009 | 2363 | 0.050 |
Why?
|
Influenza Vaccines | 1 | 2010 | 780 | 0.050 |
Why?
|
Dental Restoration, Permanent | 1 | 2023 | 130 | 0.050 |
Why?
|
Multicenter Studies as Topic | 2 | 2023 | 1727 | 0.050 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2017 | 4047 | 0.050 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2020 | 9063 | 0.050 |
Why?
|
Mycoses | 1 | 2006 | 386 | 0.050 |
Why?
|
Fever | 1 | 2010 | 1620 | 0.050 |
Why?
|
Colitis | 1 | 2011 | 1244 | 0.050 |
Why?
|
Interleukin-17 | 2 | 2020 | 922 | 0.050 |
Why?
|
Kidney | 1 | 2018 | 7063 | 0.050 |
Why?
|
Disease Progression | 6 | 2017 | 13646 | 0.050 |
Why?
|
Amoxicillin | 1 | 2023 | 182 | 0.050 |
Why?
|
Apoptosis | 3 | 2014 | 9506 | 0.050 |
Why?
|
Drug Costs | 1 | 2010 | 1196 | 0.050 |
Why?
|
Fetal Proteins | 1 | 2022 | 99 | 0.050 |
Why?
|
Ambulatory Care | 3 | 2007 | 2784 | 0.050 |
Why?
|
Resistance Training | 1 | 2024 | 199 | 0.050 |
Why?
|
Disease Models, Animal | 6 | 2020 | 18358 | 0.050 |
Why?
|
Lung | 3 | 2016 | 10087 | 0.050 |
Why?
|
Drug Combinations | 1 | 2008 | 2078 | 0.050 |
Why?
|
beta-Lactams | 1 | 2023 | 158 | 0.050 |
Why?
|
Decision Making | 1 | 2016 | 3953 | 0.050 |
Why?
|
Cell Proliferation | 4 | 2019 | 10464 | 0.050 |
Why?
|
Genomics | 1 | 2018 | 5916 | 0.050 |
Why?
|
Translocation, Genetic | 1 | 2007 | 1395 | 0.050 |
Why?
|
Macrophages | 1 | 2017 | 5796 | 0.050 |
Why?
|
Comorbidity | 3 | 2013 | 10588 | 0.050 |
Why?
|
Proto-Oncogene Proteins | 1 | 2014 | 4526 | 0.050 |
Why?
|
Succinimides | 1 | 2001 | 83 | 0.050 |
Why?
|
Skin Tests | 1 | 2023 | 639 | 0.050 |
Why?
|
Tomography, Emission-Computed | 3 | 1999 | 1126 | 0.050 |
Why?
|
Peptide Fragments | 1 | 2014 | 5151 | 0.050 |
Why?
|
Diterpenes | 1 | 2022 | 170 | 0.050 |
Why?
|
Oral Hygiene | 1 | 2022 | 132 | 0.050 |
Why?
|
Inflammation | 1 | 2021 | 10863 | 0.050 |
Why?
|
Risk Assessment | 5 | 2018 | 24316 | 0.050 |
Why?
|
Infant, Newborn | 3 | 2016 | 26410 | 0.050 |
Why?
|
Stem Cells | 1 | 2014 | 3537 | 0.050 |
Why?
|
Cell Adhesion Molecules, Neuronal | 1 | 2022 | 263 | 0.050 |
Why?
|
Polydeoxyribonucleotides | 1 | 2022 | 136 | 0.040 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 1999 | 5422 | 0.040 |
Why?
|
Histidine | 1 | 2001 | 302 | 0.040 |
Why?
|
Forehead | 1 | 2021 | 75 | 0.040 |
Why?
|
Mitochondria | 1 | 2014 | 3675 | 0.040 |
Why?
|
Benzamides | 1 | 2006 | 1380 | 0.040 |
Why?
|
Self Report | 1 | 2012 | 3766 | 0.040 |
Why?
|
Triazoles | 1 | 2006 | 904 | 0.040 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 2022 | 896 | 0.040 |
Why?
|
Ohio | 1 | 2021 | 328 | 0.040 |
Why?
|
DNA, Viral | 2 | 2019 | 2205 | 0.040 |
Why?
|
Hodgkin Disease | 1 | 2008 | 1386 | 0.040 |
Why?
|
DEAD-box RNA Helicases | 1 | 2023 | 384 | 0.040 |
Why?
|
Drug Evaluation, Preclinical | 2 | 2016 | 1339 | 0.040 |
Why?
|
Karyotyping | 2 | 2012 | 1173 | 0.040 |
Why?
|
Musculoskeletal Diseases | 1 | 2006 | 601 | 0.040 |
Why?
|
ROC Curve | 2 | 2018 | 3622 | 0.040 |
Why?
|
Mouth | 2 | 2012 | 383 | 0.040 |
Why?
|
Karnofsky Performance Status | 1 | 2019 | 167 | 0.040 |
Why?
|
Macaca nemestrina | 1 | 1999 | 20 | 0.040 |
Why?
|
Postoperative Complications | 3 | 2016 | 15854 | 0.040 |
Why?
|
Thiosemicarbazones | 1 | 1999 | 13 | 0.040 |
Why?
|
Influenza, Human | 1 | 2010 | 1539 | 0.040 |
Why?
|
Zirconium | 1 | 2020 | 110 | 0.040 |
Why?
|
Immunity, Innate | 1 | 2011 | 3079 | 0.040 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 3811 | 0.040 |
Why?
|
Mesocricetus | 1 | 1999 | 256 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2007 | 10377 | 0.040 |
Why?
|
Immunoglobulin G | 3 | 2009 | 4570 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 2 | 2017 | 1408 | 0.040 |
Why?
|
Leukocyte Count | 2 | 2014 | 1605 | 0.040 |
Why?
|
Morbidity | 2 | 2016 | 1758 | 0.040 |
Why?
|
Crohn Disease | 1 | 2011 | 2293 | 0.040 |
Why?
|
Infection Control | 1 | 2006 | 985 | 0.040 |
Why?
|
Cell Count | 2 | 2016 | 1833 | 0.040 |
Why?
|
Receptors, Complement 3d | 1 | 2018 | 117 | 0.040 |
Why?
|
Stress, Psychological | 2 | 2023 | 4543 | 0.040 |
Why?
|
Proteomics | 1 | 2012 | 3906 | 0.040 |
Why?
|
Health Status | 2 | 2011 | 4094 | 0.040 |
Why?
|
Models, Biological | 1 | 2015 | 9494 | 0.040 |
Why?
|
Prescriptions | 1 | 2021 | 388 | 0.040 |
Why?
|
Rats, Sprague-Dawley | 2 | 2000 | 8198 | 0.040 |
Why?
|
Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2001 | 450 | 0.040 |
Why?
|
Scleroderma, Localized | 1 | 2019 | 85 | 0.040 |
Why?
|
Radioisotopes | 1 | 2020 | 517 | 0.040 |
Why?
|
Autoradiography | 1 | 1999 | 732 | 0.040 |
Why?
|
Hematopoiesis | 2 | 2021 | 2058 | 0.040 |
Why?
|
Tumor Lysis Syndrome | 1 | 2018 | 38 | 0.040 |
Why?
|
Melanoma | 1 | 1996 | 5705 | 0.040 |
Why?
|
Herpesvirus 4, Human | 1 | 2023 | 1082 | 0.040 |
Why?
|
Interinstitutional Relations | 1 | 1999 | 236 | 0.040 |
Why?
|
Minnesota | 1 | 2018 | 338 | 0.040 |
Why?
|
Sex Factors | 3 | 2019 | 10656 | 0.040 |
Why?
|
Carbon Radioisotopes | 1 | 1999 | 567 | 0.040 |
Why?
|
Gene Expression | 3 | 2016 | 7595 | 0.040 |
Why?
|
Models, Statistical | 1 | 2012 | 5099 | 0.040 |
Why?
|
DNA Helicases | 1 | 2023 | 853 | 0.040 |
Why?
|
Exercise Therapy | 1 | 2024 | 941 | 0.040 |
Why?
|
Family | 2 | 2023 | 3208 | 0.040 |
Why?
|
Interferon-gamma | 2 | 2020 | 3164 | 0.040 |
Why?
|
DNA, Mitochondrial | 1 | 2023 | 871 | 0.040 |
Why?
|
Research Design | 3 | 2024 | 6209 | 0.040 |
Why?
|
Thrombopoietin | 1 | 2019 | 226 | 0.040 |
Why?
|
Gene Expression Profiling | 1 | 2013 | 9508 | 0.040 |
Why?
|
Dogs | 2 | 1999 | 3846 | 0.040 |
Why?
|
Cyclotrons | 1 | 1997 | 30 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2019 | 3520 | 0.030 |
Why?
|
Endothelial Cells | 1 | 2010 | 3587 | 0.030 |
Why?
|
Manganese | 1 | 2020 | 394 | 0.030 |
Why?
|
Costs and Cost Analysis | 4 | 2008 | 1669 | 0.030 |
Why?
|
Progesterone | 1 | 2021 | 751 | 0.030 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 3252 | 0.030 |
Why?
|
Lymphocyte Cooperation | 1 | 2016 | 112 | 0.030 |
Why?
|
Patient Acceptance of Health Care | 2 | 2023 | 3230 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2014 | 8628 | 0.030 |
Why?
|
Immune Tolerance | 2 | 2019 | 2324 | 0.030 |
Why?
|
Angiopoietin-1 | 1 | 2016 | 122 | 0.030 |
Why?
|
Chemokine CXCL9 | 1 | 2016 | 137 | 0.030 |
Why?
|
Adaptation, Psychological | 2 | 2023 | 2661 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2020 | 1839 | 0.030 |
Why?
|
Vaccination | 2 | 2022 | 3431 | 0.030 |
Why?
|
Specific Pathogen-Free Organisms | 1 | 2016 | 220 | 0.030 |
Why?
|
Neutrophils | 3 | 2016 | 3785 | 0.030 |
Why?
|
Matrix Metalloproteinase 3 | 1 | 2016 | 138 | 0.030 |
Why?
|
Piperazines | 1 | 2006 | 2552 | 0.030 |
Why?
|
Melena | 1 | 1995 | 32 | 0.030 |
Why?
|
Polyethylene Glycols | 1 | 2001 | 1195 | 0.030 |
Why?
|
Angiopoietin-2 | 1 | 2016 | 173 | 0.030 |
Why?
|
Health Maintenance Organizations | 2 | 1990 | 658 | 0.030 |
Why?
|
Recombinant Fusion Proteins | 1 | 2004 | 3728 | 0.030 |
Why?
|
Endoscopes, Gastrointestinal | 1 | 1995 | 45 | 0.030 |
Why?
|
Cricetinae | 1 | 1999 | 2423 | 0.030 |
Why?
|
Brain | 2 | 1999 | 27452 | 0.030 |
Why?
|
Lymphopoiesis | 1 | 2016 | 133 | 0.030 |
Why?
|
Immunoprecipitation | 1 | 2017 | 874 | 0.030 |
Why?
|
B-Cell Activation Factor Receptor | 1 | 2014 | 12 | 0.030 |
Why?
|
Mice, SCID | 1 | 2020 | 2632 | 0.030 |
Why?
|
Anti-Bacterial Agents | 2 | 2024 | 7458 | 0.030 |
Why?
|
Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2016 | 151 | 0.030 |
Why?
|
Dental Implants | 1 | 2023 | 807 | 0.030 |
Why?
|
Rats | 3 | 2000 | 23833 | 0.030 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2021 | 954 | 0.030 |
Why?
|
Receptors, Interleukin-21 | 1 | 2014 | 32 | 0.030 |
Why?
|
Genes, p53 | 1 | 2017 | 715 | 0.030 |
Why?
|
Social Support | 1 | 2024 | 2190 | 0.030 |
Why?
|
Chemokine CCL2 | 1 | 2017 | 606 | 0.030 |
Why?
|
Lymphocytes | 2 | 2014 | 2610 | 0.030 |
Why?
|
Head and Neck Neoplasms | 1 | 2009 | 2923 | 0.030 |
Why?
|
Osteopontin | 1 | 2016 | 306 | 0.030 |
Why?
|
Transplants | 1 | 2016 | 208 | 0.030 |
Why?
|
Platelet Count | 1 | 2017 | 784 | 0.030 |
Why?
|
Aging | 2 | 2010 | 8764 | 0.030 |
Why?
|
Menarche | 1 | 1996 | 538 | 0.030 |
Why?
|
Pentetic Acid | 1 | 2013 | 209 | 0.030 |
Why?
|
Phylogeny | 1 | 2001 | 2842 | 0.030 |
Why?
|
Janus Kinase 2 | 1 | 2017 | 561 | 0.030 |
Why?
|
Forkhead Transcription Factors | 2 | 2011 | 1622 | 0.030 |
Why?
|
Antigens, CD20 | 1 | 2014 | 199 | 0.030 |
Why?
|
Immunoglobulins | 1 | 2016 | 855 | 0.030 |
Why?
|
Recombinant Proteins | 3 | 2009 | 6512 | 0.030 |
Why?
|
Injections, Intravenous | 1 | 1995 | 1378 | 0.030 |
Why?
|
Biopsy | 2 | 2017 | 6808 | 0.030 |
Why?
|
Cross-Sectional Studies | 3 | 2023 | 26373 | 0.030 |
Why?
|
Antibody Formation | 1 | 2017 | 1393 | 0.030 |
Why?
|
Esophageal and Gastric Varices | 1 | 1995 | 214 | 0.030 |
Why?
|
Pulmonary Fibrosis | 1 | 2017 | 506 | 0.030 |
Why?
|
HLA-A Antigens | 1 | 2013 | 223 | 0.030 |
Why?
|
Algorithms | 4 | 2018 | 14154 | 0.030 |
Why?
|
Nucleic Acid Conformation | 1 | 2016 | 900 | 0.030 |
Why?
|
Yttrium Radioisotopes | 1 | 2013 | 114 | 0.030 |
Why?
|
Oxazines | 1 | 2015 | 357 | 0.030 |
Why?
|
Half-Life | 1 | 2013 | 650 | 0.030 |
Why?
|
Ethanol | 1 | 1999 | 1333 | 0.030 |
Why?
|
Candidiasis, Oral | 1 | 2012 | 57 | 0.030 |
Why?
|
Demography | 1 | 2017 | 1642 | 0.030 |
Why?
|
Infusions, Subcutaneous | 1 | 2012 | 43 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 1 | 1998 | 1794 | 0.030 |
Why?
|
Signal Transduction | 2 | 2013 | 23629 | 0.030 |
Why?
|
Area Under Curve | 1 | 2016 | 1642 | 0.030 |
Why?
|
Plasma Cells | 1 | 2016 | 599 | 0.030 |
Why?
|
Blood-Brain Barrier | 1 | 1999 | 1033 | 0.030 |
Why?
|
Glucocorticoids | 2 | 2012 | 2168 | 0.030 |
Why?
|
CD40 Ligand | 1 | 2014 | 524 | 0.030 |
Why?
|
Early Termination of Clinical Trials | 1 | 2012 | 70 | 0.020 |
Why?
|
Vision Disorders | 1 | 1999 | 1093 | 0.020 |
Why?
|
Coculture Techniques | 1 | 2016 | 1342 | 0.020 |
Why?
|
Gene Library | 1 | 2014 | 1061 | 0.020 |
Why?
|
HLA-B Antigens | 1 | 2013 | 328 | 0.020 |
Why?
|
Death | 1 | 2016 | 683 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2021 | 2846 | 0.020 |
Why?
|
Morpholines | 1 | 2015 | 584 | 0.020 |
Why?
|
Colonic Polyps | 1 | 1997 | 557 | 0.020 |
Why?
|
Deferoxamine | 1 | 2012 | 155 | 0.020 |
Why?
|
K562 Cells | 1 | 2013 | 637 | 0.020 |
Why?
|
ras Proteins | 1 | 2017 | 1058 | 0.020 |
Why?
|
Probability | 1 | 2017 | 2482 | 0.020 |
Why?
|
Medication Adherence | 1 | 2023 | 2189 | 0.020 |
Why?
|
Aminopyridines | 1 | 2015 | 580 | 0.020 |
Why?
|
Cell Separation | 1 | 2016 | 1725 | 0.020 |
Why?
|
Salivary Glands | 1 | 2012 | 231 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2015 | 2474 | 0.020 |
Why?
|
Methylprednisolone | 1 | 2012 | 387 | 0.020 |
Why?
|
Transplantation, Isogeneic | 1 | 2010 | 249 | 0.020 |
Why?
|
Interleukin-4 | 1 | 2014 | 1157 | 0.020 |
Why?
|
International Agencies | 1 | 2011 | 245 | 0.020 |
Why?
|
Solubility | 1 | 2012 | 1085 | 0.020 |
Why?
|
Cell Size | 1 | 2012 | 626 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2017 | 2201 | 0.020 |
Why?
|
Body Height | 1 | 1996 | 1568 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2016 | 2596 | 0.020 |
Why?
|
Observation | 1 | 2011 | 311 | 0.020 |
Why?
|
Sequence Analysis, DNA | 2 | 2016 | 4774 | 0.020 |
Why?
|
Splenic Rupture | 1 | 2009 | 26 | 0.020 |
Why?
|
Health Resources | 1 | 2016 | 950 | 0.020 |
Why?
|
Diagnosis, Differential | 2 | 2007 | 13019 | 0.020 |
Why?
|
Filgrastim | 1 | 2009 | 131 | 0.020 |
Why?
|
Diagnostic Self Evaluation | 1 | 2011 | 227 | 0.020 |
Why?
|
Vascular Diseases | 1 | 2018 | 1161 | 0.020 |
Why?
|
Th17 Cells | 1 | 2016 | 791 | 0.020 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily K | 1 | 2009 | 94 | 0.020 |
Why?
|
Lung Diseases | 1 | 2019 | 1925 | 0.020 |
Why?
|
Antibodies, Antinuclear | 1 | 2010 | 343 | 0.020 |
Why?
|
Dental Care for Chronically Ill | 1 | 2009 | 31 | 0.020 |
Why?
|
Interleukins | 1 | 2014 | 795 | 0.020 |
Why?
|
Immunoblotting | 1 | 2012 | 1647 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2020 | 15455 | 0.020 |
Why?
|
Leukapheresis | 1 | 2009 | 150 | 0.020 |
Why?
|
Health Promotion | 1 | 2021 | 2209 | 0.020 |
Why?
|
Odds Ratio | 2 | 2014 | 9681 | 0.020 |
Why?
|
Respiratory Function Tests | 1 | 2013 | 1696 | 0.020 |
Why?
|
Colonoscopy | 1 | 1997 | 1412 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2017 | 4120 | 0.020 |
Why?
|
Antimicrobial Cationic Peptides | 1 | 2010 | 353 | 0.020 |
Why?
|
Cause of Death | 2 | 2012 | 3728 | 0.020 |
Why?
|
Alleles | 1 | 2019 | 6892 | 0.020 |
Why?
|
Eye | 1 | 2012 | 713 | 0.020 |
Why?
|
Microscopy, Confocal | 1 | 2014 | 1972 | 0.020 |
Why?
|
Protein Processing, Post-Translational | 1 | 2016 | 1967 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8902 | 0.020 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 1995 | 1126 | 0.020 |
Why?
|
Macrocyclic Compounds | 1 | 2007 | 67 | 0.020 |
Why?
|
Calcineurin | 1 | 2008 | 236 | 0.020 |
Why?
|
Receptors, Complement 3b | 1 | 2007 | 136 | 0.020 |
Why?
|
Mental Health | 1 | 2022 | 3276 | 0.020 |
Why?
|
Chromosomes, Human, Pair 21 | 1 | 2007 | 229 | 0.020 |
Why?
|
Erythroblasts | 1 | 2007 | 142 | 0.020 |
Why?
|
Colon | 1 | 1995 | 1805 | 0.020 |
Why?
|
Mice, Nude | 1 | 2013 | 3630 | 0.020 |
Why?
|
Erythrocytes | 1 | 2016 | 2421 | 0.020 |
Why?
|
Cytogenetic Analysis | 1 | 2007 | 270 | 0.020 |
Why?
|
Cell Nucleus | 1 | 2016 | 2887 | 0.020 |
Why?
|
Skin Ulcer | 1 | 2007 | 130 | 0.020 |
Why?
|
Immune System | 1 | 2012 | 801 | 0.020 |
Why?
|
Paraneoplastic Syndromes | 1 | 2007 | 155 | 0.020 |
Why?
|
Computer Simulation | 1 | 2020 | 6277 | 0.020 |
Why?
|
Adenoma | 1 | 1997 | 2163 | 0.020 |
Why?
|
Chromosomes, Human, Pair 8 | 1 | 2007 | 453 | 0.020 |
Why?
|
Canada | 1 | 2011 | 2139 | 0.020 |
Why?
|
Professional Staff Committees | 1 | 2005 | 37 | 0.020 |
Why?
|
Phosphorylation | 1 | 2017 | 8326 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2011 | 3585 | 0.020 |
Why?
|
Liver | 2 | 2012 | 7570 | 0.020 |
Why?
|
Eczema | 1 | 2007 | 245 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2007 | 881 | 0.020 |
Why?
|
Myeloid Cells | 1 | 2010 | 832 | 0.010 |
Why?
|
Epidermis | 1 | 2007 | 539 | 0.010 |
Why?
|
Colonic Neoplasms | 1 | 1997 | 2542 | 0.010 |
Why?
|
Serologic Tests | 1 | 2007 | 383 | 0.010 |
Why?
|
Plasma Exchange | 1 | 2005 | 160 | 0.010 |
Why?
|
Sensitivity and Specificity | 2 | 2016 | 14736 | 0.010 |
Why?
|
Hyperplasia | 1 | 2007 | 1152 | 0.010 |
Why?
|
Molecular Targeted Therapy | 1 | 2016 | 2830 | 0.010 |
Why?
|
Meta-Analysis as Topic | 1 | 2009 | 1364 | 0.010 |
Why?
|
Health Services for the Aged | 1 | 1987 | 258 | 0.010 |
Why?
|
Sick Role | 1 | 2005 | 229 | 0.010 |
Why?
|
Blood Transfusion | 1 | 2011 | 1309 | 0.010 |
Why?
|
Exercise | 1 | 2021 | 5947 | 0.010 |
Why?
|
Organ Size | 1 | 2009 | 2268 | 0.010 |
Why?
|
Protein Binding | 1 | 2016 | 9346 | 0.010 |
Why?
|
Down-Regulation | 1 | 2011 | 2937 | 0.010 |
Why?
|
Albumins | 1 | 2007 | 577 | 0.010 |
Why?
|
Glycoproteins | 1 | 2012 | 2204 | 0.010 |
Why?
|
Self-Assessment | 1 | 2006 | 401 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2023 | 12775 | 0.010 |
Why?
|
Rabbits | 1 | 2010 | 4782 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2012 | 6238 | 0.010 |
Why?
|
Immunotherapy | 1 | 2019 | 4740 | 0.010 |
Why?
|
Major Histocompatibility Complex | 1 | 2006 | 877 | 0.010 |
Why?
|
Intestines | 1 | 2012 | 1911 | 0.010 |
Why?
|
Pyridines | 1 | 2015 | 2889 | 0.010 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2009 | 1362 | 0.010 |
Why?
|
Hospitalization | 1 | 2023 | 10844 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 3 | 2012 | 36849 | 0.010 |
Why?
|
Quality-Adjusted Life Years | 1 | 2009 | 1735 | 0.010 |
Why?
|
Receptors, Interleukin-2 | 1 | 2004 | 564 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2010 | 21163 | 0.010 |
Why?
|
Geriatric Assessment | 1 | 1990 | 1422 | 0.010 |
Why?
|
Salmo salar | 1 | 2001 | 7 | 0.010 |
Why?
|
Hydroxylamine | 1 | 2001 | 17 | 0.010 |
Why?
|
Macropodidae | 1 | 2001 | 12 | 0.010 |
Why?
|
Encephalomyocarditis virus | 1 | 2001 | 21 | 0.010 |
Why?
|
Cardiovirus Infections | 1 | 2001 | 20 | 0.010 |
Why?
|
Autoantibodies | 1 | 2010 | 2126 | 0.010 |
Why?
|
Alkylation | 1 | 2001 | 84 | 0.010 |
Why?
|
Isomerism | 1 | 2001 | 198 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8750 | 0.010 |
Why?
|
Drug Interactions | 1 | 2006 | 1420 | 0.010 |
Why?
|
Double-Blind Method | 1 | 1995 | 12457 | 0.010 |
Why?
|
Administration, Oral | 1 | 2009 | 4043 | 0.010 |
Why?
|
Creatinine | 1 | 2006 | 1915 | 0.010 |
Why?
|
Hydrolysis | 1 | 2001 | 648 | 0.010 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 2001 | 1056 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2019 | 16027 | 0.010 |
Why?
|
Amino Acid Sequence | 2 | 2001 | 13425 | 0.010 |
Why?
|
Life Change Events | 1 | 2005 | 962 | 0.010 |
Why?
|
Referral and Consultation | 2 | 1990 | 3627 | 0.010 |
Why?
|
Interferon-beta | 1 | 2001 | 349 | 0.010 |
Why?
|
Amino Acid Motifs | 1 | 2001 | 928 | 0.010 |
Why?
|
Molecular Sequence Data | 2 | 2001 | 17626 | 0.010 |
Why?
|
Biological Assay | 1 | 2001 | 627 | 0.010 |
Why?
|
DNA, Complementary | 1 | 2001 | 1992 | 0.010 |
Why?
|
Brain Neoplasms | 1 | 1999 | 9197 | 0.010 |
Why?
|
Rhode Island | 2 | 1990 | 353 | 0.010 |
Why?
|
Prevalence | 1 | 2015 | 15868 | 0.010 |
Why?
|
Rats, Inbred Lew | 1 | 1999 | 1165 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2001 | 2750 | 0.010 |
Why?
|
Sequence Alignment | 1 | 2001 | 2177 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2013 | 17132 | 0.010 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2001 | 2487 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2014 | 20224 | 0.010 |
Why?
|
Reoperation | 1 | 2006 | 4340 | 0.010 |
Why?
|
Ultrasonography | 1 | 2009 | 6001 | 0.010 |
Why?
|
Interleukin-10 | 1 | 2001 | 1184 | 0.010 |
Why?
|
Boston | 1 | 2008 | 9371 | 0.010 |
Why?
|
Amphotericin B | 1 | 1976 | 143 | 0.010 |
Why?
|
Biomedical Research | 1 | 2011 | 3464 | 0.010 |
Why?
|
Rats, Wistar | 1 | 1999 | 1890 | 0.010 |
Why?
|
Lipids | 1 | 2006 | 3344 | 0.010 |
Why?
|
Phenotype | 1 | 2012 | 16716 | 0.010 |
Why?
|
Kidney Failure, Chronic | 1 | 2006 | 2491 | 0.010 |
Why?
|
Databases, Factual | 1 | 2008 | 8072 | 0.010 |
Why?
|
Emotions | 1 | 2005 | 2768 | 0.010 |
Why?
|
Binding Sites | 1 | 2001 | 6018 | 0.010 |
Why?
|
Drug Eruptions | 1 | 1976 | 336 | 0.010 |
Why?
|
Mutation, Missense | 1 | 2001 | 2593 | 0.010 |
Why?
|
Cystic Fibrosis | 1 | 2001 | 1285 | 0.010 |
Why?
|
Base Sequence | 1 | 2001 | 12421 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2007 | 11659 | 0.010 |
Why?
|
Anxiety | 1 | 2005 | 4675 | 0.010 |
Why?
|
Mass Screening | 1 | 2005 | 5451 | 0.000 |
Why?
|
Equipment Design | 1 | 1997 | 3529 | 0.000 |
Why?
|
DNA | 1 | 2001 | 7211 | 0.000 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2005 | 4637 | 0.000 |
Why?
|
Cardiovascular Diseases | 1 | 2011 | 15652 | 0.000 |
Why?
|
Random Allocation | 1 | 1990 | 2397 | 0.000 |
Why?
|
Depression | 1 | 2005 | 8241 | 0.000 |
Why?
|
Internal Medicine | 1 | 1990 | 1057 | 0.000 |
Why?
|
Eosinophilia | 1 | 1976 | 556 | 0.000 |
Why?
|